ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ACAD Acadia Pharmaceuticals Inc

17.29
0.24 (1.41%)
Last Updated: 18:34:27
Delayed by 15 minutes
Share Name Share Symbol Market Type
Acadia Pharmaceuticals Inc NASDAQ:ACAD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.24 1.41% 17.29 17.28 17.30 17.35 16.81 16.94 497,907 18:34:27

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Acadia Pharmaceuticals Inc. of Pendency of Class Action Laws...

08/05/2015 6:24pm

GlobeNewswire Inc.


Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Acadia Pharmaceuticals Charts.

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common shares of ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) between February 26, 2015 and March 11, 2015.

You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of California. If you purchased or otherwise acquired ACADIA Pharmaceuticals Inc. ("ACADIA") securities between February 26, 2015 and March 11, 2015, your rights may be affected by this action. To get more information at no cost or obligation to you, go to:

HTTP://ZLK.9NL.COM/ACAD-INFOSHEET

The complaint alleges that the Company made false and misleading statements and/or failed to disclose material information regarding the timing of its submission of its New Drug Application to the FDA for Nuplazid.

On March 11, 2015, the Company announced it would delay submitting a New Drug Application for its drug Nuplazid. The Company also noted that Chief Executive Officer Uli Hacksell is retiring. Shares of ACADIA were down more than 20% on intraday trading the following day.

If you suffered a loss in Acadia you have until May 12, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/acadia-pharmaceuticals-acad.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP
         Eduard Korsinsky, Esq.
         30 Broad Street - 24th Floor
         New York, NY 10004
         Tel: (212) 363-7500
         Toll Free: (877) 363-5972
         Fax: (212) 363-7171
         www.zlk.com

1 Year Acadia Pharmaceuticals Chart

1 Year Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock